Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Novo Nordisk is planning a new Phase III trial for CagriSema ... dose subgroup by the end of the follow-up, weight loss had not started to plateau. "This suggests that additional weight loss ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

and Novo plans in early 2026 to ask for regulatory approval of CagriSema. Novo, which pioneered the use of GLP-1 medicines like Wegovy for weight loss, is in a tight competition with Eli Lilly.

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was ... Among this high-dose group, weight loss had not started to plateau at the 68-week timepoint ...

The company also tried to reassure investors about CagriSema's effectiveness. Jorgensen said some people lost weight very quickly, and another group lost weight continuously, showing no sign of ...

Novo Nordisk A/S, No. 25-cv-00713 ... claim the company misrepresented the likelihood of CagriSema achieving at least 25% weight loss in the study. The suit alleges that Novo Nordisk created ...

The amycretin data looks stronger than the 19% weight loss at 36 weeks generated for Lilly’s next-generation drug retatrutide in phase 2 (phase 3 data is expected in 2026) and 20.4% cagrisema ...